
may pm et
summari diversifi global manufactur life scienc chemic analysi instrument agil
spun-off electron measur unit
nm price-to-earnings oper ep
risk assess reflect volatil agil
result past off-set recent effort streamlin
busi divest part portfolio
contribut variabl
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop see
et cfra keep hold
lower
target line peer
forward ep estim
apr-q ep vs
ahead view lower fy oct
estim sale rose line
forecast life scienc appli
market crosslab group
diagnost genom howev
agil guid jul-q sale
mid-point year
ago growth forecast agil
also guid jul-q ep
initi forecast end-market
pharmaceut market remain robust
sale strong mass spectrometri
sale chemic energi rose
rise last year howev food
market mainli due impact
chines govern reorgan
food safeti ministri think
reorgan slow instrument
purchas china
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview spun hewlett-packard
provid investor exposur commun electron life scienc chemic analysi
diagnost genom industri novemb agil spun electron measur unit
account sale new publicli trade compani
within life scienc diagnost agil focus pharmaceut valu chain area
therapeut research discoveri develop clinic trial manufactur qualiti assur
qualiti control pharmaceut biopharmaceut market agil instrument help
lower cost discov develop new drug also exposur academ
govern market includ academ institut larg govern institut privat
fund organ chemic analysi focus primarili follow area petrochem
environment homeland secur forens bioagricultur food safeti materi scienc
diagnost genom focus clinic academ govern pharmaceut
biotech market product fall seven main area work patholog product specif protein
flow reagent target enrich cytogenet research solut microarray nucleic acid qualiti
control molecular biolog product
impact major develop may agil complet acquisit varian billion
cash per share varian lead supplier scientif instrument vacuum technolog
life scienc environment energi appli research applic june agil
complet acquisit denmark-bas dako billion largest deal histori dako
provid antibodi reagent scientif instrument softwar primarili patholog laboratori
cancer diagnost dako revenu approxim million
novemb agil spun electron measur unit separ publicli trade
compani new agil compos chemic analysi life scienc
diagnost genom unit gener billion sale presid mike mcmullen
assum ceo posit march follow retir sullivan octob agil
close nuclear magnet reson unit
financi trend think numer restructur announc divestitur spin-off
taken place past sever year benefit agil longer term stabl earn
fy oct agil report sale billion fy report sale billion
fy sale billion follow spin-off electron measur unit
account sale fy agil sale billion declin primarili
due declin electron measur largest divis sale
offset benefit acquisit dako june fy agil sale inclus
dako acquisit billion increas agil sale inclus varian acquisit
billion fy increas fy compani believ overal
measur market repres billion market opportun end fy broken
follow manner life scienc billion chemic analysi billion electron measur
billion believ long-term growth rate respect market life scienc
chemic analysi electron measur anticip modest growth
agil measur test busi forese futur think abl outpac
aforement growth trend combin organ growth strateg acquisit
compani see fit
novemb follow spin-off electron measur unit publicli trade keysight
technolog agil reorgan three busi segment life scienc appli market group
lsag agil crosslab group acg diagnost genom dgg
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
life scienc tool servic sub-industri
next month may congress
approv billion increas nation
institut nih fy budget
billion septemb
billion increas fy budget
increas contrast presid
trump call cut nih budget
billion billion fy fy
signific fund academ lab
turn account sale life
scienc tool compani averag
trump propos indic
administr prioriti actual fund
determin congress think
signific bipartisan support nih
believ congress disregard trump propos
cut nih budget nonetheless trump
propos budget creat uncertainti
may result project termin
cloud futur research project
view nih budget rose
billion billion
largest percentag increas sinc
includ billion stimulu fund
american recoveri reinvest act
arra
howev note mani life scienc
compani activ pursu initi
commerci non-academ govern
revenu base also see budget issu
europ result soft govern fund
decemb presid obama sign
centuri cure act law law
provid billion year
nation institut split
go cancer moonshot billion
fund precis medicin initi
billion fund brain initi
support alzheim diseas research
overal see mid-single-digit sale growth
emerg market china
remain robust growth region grow
rate mid-teen help fuel overal
industri growth believ demand
strong begin moder
think research lab suffici
equip current need mani
equip compani also diversifi
product line increas sale
consum typic immun
budget constraint expand
area environment food
safeti agricultur growth
end-market expect robust
pharmaceut research
compani provid servic
pharmaceut biotech firm
contract research organ see
solid growth next month
view believ pharmaceut biotech
firm increasingli outsourc servic
think increas effici lower
cost also see increas strateg
 life scienc tool
servic rose vs rise
 composit index year date
april life scienc
declin composit
base index
five-year market price perform jun
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
estim sale rose broad-bas growth across busi unit
geographi led china sale grew life scienc appli
market sale rose agil crosslab rose diagnost genom
rose oper margin grew pharma end-market remain
robust academia govern soft primarili show
stabil europ /jeffrey loo cfa
analyst research note compani news
et cfra keep hold opinion share agil
lower target line peer
forward ep estim apr-q ep vs
ahead view lower fy oct estim
sale rose line forecast life scienc appli
market crosslab group diagnost genom
howev agil guid jul-q sale
mid-point year ago growth forecast agil also
guid jul-q ep initi forecast
end-market pharmaceut market remain robust sale
mass spectrometri sale chemic energi rose rise
last year howev food market mainli due impact
chines govern reorgan food safeti ministri think
reorgan slow instrument purchas china
et cfra keep hold opinion share agil
inc rais target
peer fy oct ep estim set
jan-q ep vs ahead view
sale grew forecast broad-bas growth see
continu throughout lsag unit rose crosslab
diagnost genom rose oper margin rose mark
consecut quarter improv margin see particular robust demand
chemic unit grew doubl digit consecut
rais target peer
forward ep jul- ep vs ahead
estim rais fy oct fy ep estim
sale rose growth forecast sale
life scienc unit rose crosslab diagnost genom
oper margin rose repres straight
quarter improv oper margin encourag broad-bas
growth aid rebound chemic end-market /jeffrey loo cfa
et cfra keep hold opinion share agil
inc rais target
peer fy oct ep estim faster
growth apr-q ep vs ahead view sale rose
aid improv sale chemic energi unit follow modest
growth last quarter straight quarter declin chemic
agil crosslab diagnost genom oper margin rose
robust mark agil straight quarter improv margin
et capit iq keep hold opinion share
agil rais target price
slightli peer next month ep estim
better margin expans set fy oct ep estim jan-q
ep vs ahead estim sale rose
growth forecast strong demand china particularli food
test rebound chemic sale seven straight quarter
year-over-year declin life scienc appli market sale rose
crosslab diagnost oper incom rose
inc keep month target
price in-lin peer revis fy oct ep estim
oct-q ep vs ahead
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn per
share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
